The clinical developments and future of the COX-2 inhibitor drugs

Author： Goldstein Jerome  

Publisher： VSP

ISSN： 1568-5608

Source： Inflammopharmacology, Vol.9, Iss.1-2, 2001-05, pp. : 91-99

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical pharmacology of celecoxib, a COX-2 selective inhibitor

By Antoniou Katerina   Malamas Michael   Drosos Alexandros A  

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 11, 2007-08 ,pp. : 1719-1732

Informa Healthcare

Access to resources Recommend Favorite

Clinical pharmacology of etoricoxib: a novel selectiveCOX2 inhibitor

By Patrignani Paola   Capone Marta L   Tacconelli Stefania  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 2, 2003-02 ,pp. : 265-284

Informa Healthcare

Access to resources Recommend Favorite

Concomitant Use of Gastroprotective Drugs among Elderly NSAID/COX-2 Selective Inhibitor Users: A Nationwide Register-Based Study

By Johnell Kristina   Fastbom Johan  

Clinical Drug Investigation, Vol. 28, Iss. 11, 2008-01 ,pp. : 687-695

Adis International

Access to resources Recommend Favorite

A Safety Monitoring Procedure for a Clinical Drug Development Program, with Application to the Assessment of a Novel COX-2 Inhibitor

By Bolland Kim  

Journal of Biopharmaceutical Statistics, Vol. 18, Iss. 4, 2008-07 ,pp. : 737-749

Taylor & Francis Ltd

Access to resources Recommend Favorite

Reports of COX-2 inhibitor-associated arrhythmias in NZ

By  

Reactions Weekly, Vol. 1, Iss. 1076, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite